Candel Therapeutics, Inc. (CADL)
NASDAQ:CADL
Want to see CADL full AI Analyst Report?
CADL Stock Chart & Stats
$6.37
$0.00(0.00%)
At close: 4:00 PM EST
$6.37
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$4.35 - $9.57
Previous CloseN/A
Volume524.53K
Average Volume (3M)2.08M
Market Cap
$623.53M
Enterprise Value$262.64M
Total Cash (Recent Filing)$194.83M
Total Debt (Recent Filing)$1.80M
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Aug 19, 2026EPS Estimate
-0.24Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.98
Shares Outstanding73,270,240
10 Day Avg. Volume1,793,831
30 Day Avg. Volume2,078,322
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)5.76
Price to Sales (P/S)0.00
P/FCF Ratio-7.69
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.22
Forecast
1Y Price Target
$21.50Price Target Upside237.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.98
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Phase 3 Clinical ProgressRobust Phase 3 follow-up data indicating accumulating clinical benefit materially de-risks the lead program versus earlier stages. Over 2–6 months this strengthens regulatory and commercial optionality, boosts partner interest, and supports future milestone and royalty revenue potential.
Differentiated Viral Immunotherapy PlatformCandel’s engineered viral platforms and intratumoral approach provide a durable competitive advantage: modular technology can be applied across indications, supports combination strategies with standard therapies, and creates multiple commercialization pathways (partnering, licensing, or internal launch).
Improved Balance Sheet And Low LeverageMaterially higher equity and minimal debt give the company financing flexibility to fund late-stage programs over the coming months. Low leverage reduces near-term refinancing pressure and provides runway to advance pivotal programs or negotiate strategic partnerships.
Bears Say
Pre-revenue Business ModelWith no approved products or recurring sales, the firm’s economics rely on uncertain collaboration payments and milestone timing. This structurally increases revenue volatility and ties near-term financing and valuation prospects to clinical outcomes rather than operating cash generation.
Persistent Cash Burn And Negative FCFSignificant, ongoing negative operating cash flow requires repeated financing to sustain development. Over a multi-month horizon this elevates dilution and execution risk, forcing management to prioritize programs and increasing the chance of funding-driven delays or partnership dependence.
Sustained Net Losses And Negative ReturnsLarge, persistent losses and deeply negative ROE underscore inability to generate profits from operations. Structurally, this limits internal self-funding for commercialization and amplifies reliance on capital markets or partners, raising long-term dilution and viability risks if clinical setbacks occur.
Candel Therapeutics News
CADL FAQ
What was Candel Therapeutics, Inc.’s price range in the past 12 months?
Candel Therapeutics, Inc. lowest stock price was $4.35 and its highest was $9.57 in the past 12 months.
What is Candel Therapeutics, Inc.’s market cap?
Candel Therapeutics, Inc.’s market cap is $623.53M.
When is Candel Therapeutics, Inc.’s upcoming earnings report date?
Candel Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 72 days.
How were Candel Therapeutics, Inc.’s earnings last quarter?
Candel Therapeutics, Inc. released its earnings results on May 14, 2026. The company reported -$0.14 earnings per share for the quarter, beating the consensus estimate of -$0.296 by $0.156.
Is Candel Therapeutics, Inc. overvalued?
According to Wall Street analysts Candel Therapeutics, Inc.’s price is currently Undervalued.
Does Candel Therapeutics, Inc. pay dividends?
Candel Therapeutics, Inc. does not currently pay dividends.
What is Candel Therapeutics, Inc.’s EPS estimate?
Candel Therapeutics, Inc.’s EPS estimate is -0.24.
How many shares outstanding does Candel Therapeutics, Inc. have?
Candel Therapeutics, Inc. has 73,270,240 shares outstanding.
What happened to Candel Therapeutics, Inc.’s price movement after its last earnings report?
Candel Therapeutics, Inc. reported an EPS of -$0.14 in its last earnings report, beating expectations of -$0.296. Following the earnings report the stock price went down -0.336%.
Which hedge fund is a major shareholder of Candel Therapeutics, Inc.?
Currently, no hedge funds are holding shares in CADL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Candel Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$21.50 (237.52% Upside)
$21.50 (237.52% Upside)
Blogger Sentiment
Bullish
CADL Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 156.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 12.1%
Last 30 Days ▲ 12.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.33%
12-Months-Change
Fundamentals
Return on Equity
-60.42%
Trailing 12-Months
Asset Growth
110.54%
Trailing 12-Months
Company Description
Candel Therapeutics, Inc.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company develops CAN-2409, which is in Phase II clinical trails for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. It also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent glioblastoma. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. The company was incorporated in 2003 and is based in Needham, Massachusetts.
CADL Stock 12 Month Forecast
Average Price Target
$21.50
▲(237.52% Upside)
Technical Analysis
Tonix Pharma
―
Quantum-Si
―
Humacyte
―
Monte Rosa Therapeutics
―
Inhibrx Biosciences Inc
―
Ownership Overview
9.51% Insiders
17.25% Mutual Funds
28.22% Other Institutional Investors
38.09% Public Companies and
Individual Investors